Table 1.

MUC1 HLA-A2-, HLA-A3-, and HLA-A24-binding peptides and potential agonists, with predicted binding and T2-cell binding assay

Peptide	Location	Position	Sequence	Class I allele	Predicted binding*	Actual binding#
C1	C domain	1172–1181	ALAIVYLIAL	A2	49	249
C1A			YLAIVYLIAL		226	245
C2	C domain	1177–1186	YLIALAVCQC	A2	52	211
C2A			YLIALAVCQV		736	299
C3	C domain	1240–1248	SLSYTNPAV	A2	70	326
C3A			YLSYTNPAV		320	342
V1	VNTR region	150–158	STAPPAHGV	A2	1	166
V1A			YLAPPAHGV		320	486
V2	VNTR region	141–149	APDTRPAPG	A2	0	210
V2A			YLDTRPAPV		128	647
C4	C domain	432–441	ALAIVYLIAL	A3	5	NA
C4A			ALFIVYLIAK		900	NA
C5	C domain	483–491	STDRSPYEK	A3	3	NA
C5A			SLFRSPYEK		300	NA
C6	C domain	462–471	TYHPMSEYPT	A24	6	NA
C6A			KYHPMSEYAL		480	NA
C7	C domain	502–510	SYTNPAVAA	A24	5	NA
C7A			KYTNPAVAL		400	NA

Amino acids that were changed to generate an agonist epitope are in bold

* Predicted binding on the basis of reported motif [32]; score estimate of half time of disassociation of a molecule containing this sequence.

^#Peptides were used at a concentration of 12.5 μg/ml in a binding assay with T2-A2 cells. Results are expressed as mean fluorescence intensity (MFI). NA: A functional binding assay was not available for HLA-A3 and HLA-A24 peptides